Argos Therapeutics to Present at the Annual Sachs Immuno-Oncology: BD&L and Investment Forum
May 29, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 29, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
Argos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015
May 20, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
Argos Therapeutics Reports First Quarter 2015 Financial Results and Operational Highlights
May 14, 2015 16:05 ET
|
Argos Therapeutics, Inc.
-Interim data analyses from the phase 3 ADAPT trial at approximately 25% of events expected during ASCO Annual Meeting-
- Conference Call and Webcast Today, May 14th, at 4:30 p.m. ET -
DURHAM,...
Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial
May 13, 2015 17:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 13, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
Argos Therapeutics to Present at 36th American Society for Apheresis Annual Meeting
May 08, 2015 09:44 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 8, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized...
Argos Therapeutics to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015
May 07, 2015 16:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., May 7, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies...
Argos Therapeutics Recognized for Economic Development at the 17th Annual Triangle CREW Champion Awards
April 23, 2015 10:15 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., April 23, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized...
Argos Therapeutics Announces Publication of Data From Phase 2 Clinical Trial of AGS-003 Fully Personalized Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma (mRCC)
April 21, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., April 21, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized...
Argos Therapeutics to Present Update on Pivotal Phase 3 ADAPT Clinical Trial During 2015 ASCO Annual Meeting
April 20, 2015 08:30 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., April 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized...
Argos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in China
April 14, 2015 08:00 ET
|
Argos Therapeutics, Inc.
DURHAM, N.C., April 14, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized...